Clinical trial
Antihypertensive Efficacy and Safety of Candesartan/HCT 32/12.5 and 32/25 mg in…
NCT00383929 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00383929 |
|---|---|
| Title | Antihypertensive Efficacy and Safety of Candesartan/HCT 32/12.5 and 32/25 mg in Comparison With Candesartan 32 mg |
| Official title | A Double Blind, Randomised, 3-Arm Parallel Group, Multicentre, 8-Week, Phase III Study to Assess Antihypertensive Efficacy and Safety of the Combination of Candesartan Cilexetil (CC) /HCT 32/12.5mg and 32/25mg vs. CC 32mg Alone in Patients With Inadequate BP Control on Monotherapy With CC 32mg |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hypertension |
| Intervention type | Drug |
| Interventions | Candesartan cilexetil, Hydrochlorothiazide |
| Enrollment | 1,979 |
| Start date | Sep 1, 2006 |
| Primary completion | Aug 1, 2007 |
| Completion | Oct 1, 2007 |
| First posted | Oct 4, 2006 |
| Last update posted | Mar 20, 2008 |
| Countries | Denmark, Estonia, France, Germany, Lithuania, Netherlands, Poland, Serbia and Montenegro, Sweden, Ukraine, United Kingdom |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: